Internal Medicine · 2018 · 31 citations · 14 references
MedicineOncologyPharmacologyImmunotherapyTumor ImmunologyTumor ProgressionCancer ImmunotherapyImmune Checkpoint InhibitorsImmunotherapy For Solid TumorsLung CancerTumor-associated AntigensTumor-associated MacrophagesImmunohistochemical MarkersImmunohistochemical StainingMonoclonal Antibodies In OncologyNon-small Cell Lung Cancer ImmunotherapyNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentPd-l1 BlockadeProgrammed Death-ligand 1 Inhibition
Pulmonary pleomorphic carcinoma (PPC) is a rare very aggressive subtype of non-small cell lung cancer. We herein report a case of PPC that showed a rapid response to nivolumab. The patient, whose multiple tumors had progressed very aggressively, was treated with nivolumab, an anti-programmed cell death-1 (PD-1) antibody. The tumors dramatically shrank after one cycle of nivolumab. The tumors were positive for programmed cell death ligand 1 (PD-L1). An immunohistochemical analysis revealed numerous PD-1+, CD68+ and CD206+ macrophages. This PD-1 antibody may be a good treatment option, especially in tumors that express PD-L1 and which show PD-1+ macrophage infiltration.
14
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al. · New England Journal of Medicine · 2016 · 10.1K citations · Full text
Medicine, Oncology, Pharmacology +17
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei, L. Paz-Ares, Leora Horn et al. · New England Journal of Medicine · 2015 · 9.5K citations · Full text
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Sydney R. Gordon, Roy L. Maute, Ben W. Dulken et al. · Nature · 2017 · 2.3K citations · Full text
Life Sciences, Immunology, Oncology +16